Holen Sie sich die Stockscreener-App
4.02
1.47%
-0.06
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Will Altimmune Inc. stock benefit from upcoming earnings reports2025 Earnings Surprises & Advanced Technical Signal Analysis - ulpravda.ru
Enovix, Serve Robotics, EOG, Altimmune, Globalstar Shake Markets - TipRanks
Wayne Pisano Increases Stake in Altimmune Inc with Recent Share Purchase - GuruFocus
Altimmune, Inc. (ALT) Stock Analysis: Exploring A Potential 335% Upside In Biotech - DirectorsTalk Interviews
Altimmune (ALT) Is Up 13.0% After FDA Breakthrough Tag For Pemvidutide In MASHHas The Bull Case Changed? - Yahoo Finance
Can Altimmune Inc. stock sustain free cash flow growthJuly 2025 Volume & Momentum Based Trading Ideas - ulpravda.ru
Published on: 2026-01-09 03:53:26 - ulpravda.ru
Entry Recap: Will Altimmune Inc. stock split attract more investors2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - ulpravda.ru
Will Altimmune Inc. stock split attract more investorsPortfolio Return Summary & Fast Moving Market Watchlists - ulpravda.ru
Swing Trade: Why Altimmune Inc. stock remains on buy listsJuly 2025 Selloffs & Smart Allocation Stock Reports - ulpravda.ru
Altimmune (ALT) Is Up 16.1% After FDA Breakthrough Nod For AI-Enhanced MASH Drug Trial – Has The Bull Case Changed? - simplywall.st
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH - The Globe and Mail
Altimmune gains on FDA breakthrough designation for MASH therapy - MSN
Altimmune’s Surprising Stock Surge: What’s Behind It? - StocksToTrade
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Altimmune shares rally after FDA awards breakthrough status to pemvidutide - MSN
Why Did Mobileye Stock Surge 8% Pre-Market Today? - Stocktwits
Altimmune (ALT) Surges on FDA Breakthrough Therapy Designation f - GuruFocus
Altimmune Receives FDA Breakthrough Therapy Designation For Pemvidutide In Mash - TradingView — Track All Markets
Altimmune stock gains on FDA breakthrough status (ALT:NASDAQ) - Seeking Alpha
FDA grants breakthrough therapy status to Altimmune’s MASH drug By Investing.com - Investing.com Australia
Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug - TradingView — Track All Markets
Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Quiver Quantitative
Altimmune stock soars after FDA grants Breakthrough Therapy status By Investing.com - Investing.com Canada
Altimmune stock soars after FDA grants Breakthrough Therapy status - Investing.com
FDA grants breakthrough therapy status to Altimmune’s MASH drug - Investing.com
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH - The Manila Times
FDA flags new liver disease drug for faster review after promising early data - Stock Titan
Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug - Stocktwits
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - MSN
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround - The Globe and Mail
Jerome Durso Buys Handful Of Shares In Altimmune - Yahoo Finance
Insider Buying: Altimmune Independent Chairman Bought US$52k Of Shares - simplywall.st
Altimmune, Pure Storage, Globalstar, Cipher Mining, AutoZone Shake-Up - TipRanks
Altimmune announces CEO transition - MSN
Q3 2025 Altimmune Inc Earnings Call Transcript - GuruFocus
Does Altimmune (ALT) have the potential to rally 229.28% as Wall Street analysts expect? - MSN
Insider Buying: John Gill Acquires 12,500 Shares of Altimmune In - GuruFocus
Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen - Seeking Alpha
John Gill Acquires 12,500 Shares of Altimmune (NASDAQ:ALT) Stock - MarketBeat
Altimmune Director John Gill Acquires 12,500 Shares - TradingView — Track All Markets
Altimmune stock soars over 10% premarket on positive mid-stage data for liver disease treatment drug - MSN
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Insider Buying: Jerome Durso Acquires 12,500 Shares of Altimmune Inc (ALT) - GuruFocus
Altimmune (NASDAQ:ALT) Director Jerome Benedict Durso Purchases 12,500 Shares - MarketBeat
Altimmune’s 48-Week MASH Data Still Leave Doubts On Fibrosis Benefit - Citeline News & Insights
Altimmune Director Jerome Benedict Durso Acquires 12,500 Shares - TradingView — Track All Markets
Altimmune: Positives And Negatives Of The IMPACT Data And Recent Updates - Seeking Alpha
Altimmune Slides As Insider Purchases Lose Another US$15k - 富途牛牛
Altimmune Stock Plummets After Disappointing Trial Results - timothysykes.com
Would You Still Hold Altimmune Stock If It Fell Another 30%? - Trefis
Can Altimmune Inc. stock hit analyst price targetsJuly 2025 Reactions & Weekly Watchlist for Hot Stocks - Улправда
How Altimmune Inc. stock compares to market leadersPortfolio Risk Report & Weekly Setup with High ROI Potential - Улправда
Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASHSlideshow (NASDAQ:ALT) 2025-12-19 - Seeking Alpha
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):